On the stock market since 2021, it operates in the world of health and science. It has 76 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The average analyst price target is $29.00 — 26% above today’s price.
A loss of $696.0M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 75 sells against just 15 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, VOR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: VOR is a high-risk stock — not yet profitable, and its future rides on its product catching on.